A clinical trail to study the effects of alpha blocker tamsulosin and drug combination alpha blocker tamsulosin and competitive muscarinic-receptor antagonist solifenacin in treatment with ureteral stent related lower urinary tract symptoms.
Completed
- Conditions
- Calculus of urinary tract in diseases classified elsewhere,
- Registration Number
- CTRI/2020/04/024945
- Lead Sponsor
- ankit
- Brief Summary
To analyse the effectiveness of selective alpha -1-blocker tamsulosin and combination of alpha -1-blocker tamsulosin plus competitve muscarinic receptor antagonist solifenacin in improving the lower urinary tract symptoms of patients with double J ureteral stents
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients undergoing Double-J stenting for ureteral intervention were included in the study.
Exclusion Criteria
- 1-Patients who were previously diagnosed with benign prostatic hyperplasia or overactive bladder.
- 2-Pregnant women.
- 3- Psychiatric illness 4-Urinary tract infections.
- 5-Previous use of selective alpha-1- blocker and or antimuscarinic agent or with known history of orthostatic hypotension,allergy,hypersensitivity to one or more alpha blockers.
- 6-Patients under ICU management 7-Patients on dialysis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2.visual analogue pain scale 1. On the day of PER URETHRAL CATHETER REMOVAL | 2.On the day of DJ stent removal 1. International Prostate Symptom Score/quality of life 1. On the day of PER URETHRAL CATHETER REMOVAL | 2.On the day of DJ stent removal
- Secondary Outcome Measures
Name Time Method 1. STORAGE SYMPTOMS IMPROVEMENT 2. VOIDING SYMPTOMS IMPROVEMENT
Trial Locations
- Locations (1)
Dr. PSIMS AND RF
🇮🇳Krishna, ANDHRA PRADESH, India
Dr. PSIMS AND RF🇮🇳Krishna, ANDHRA PRADESH, IndiaAnkit anandPrincipal investigator8601304196Dr.ankitanand19@gamil.com